Globia Exports

Semanext is a prescription‑only injectable medicine containing semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist. Semaglutide works by enhancing insulin secretion when blood sugar is elevated, reducing glucagon release, slowing gastric emptying, and decreasing appetite — actions that help improve blood glucose control and, when used as part of a comprehensive treatment plan, support metabolic health. It is typically supplied in pre‑filled pens that deliver once‑weekly subcutaneous injections, with initial dose levels often started at lower strengths such as 0.5 mg and, if tolerated and prescribed, increased to higher strengths such as 1 mg. The medication should be administered exactly as directed by a healthcare professional and used alongside a balanced diet and exercise regimen. Common side effects may include nausea, vomiting, diarrhea, constipation, or headache; regular follow‑up with a clinician is recommended to ensure safe and effective treatment. GLP‑1 receptor agonist therapies like semaglutide are increasingly used for chronic metabolic conditions, including type 2 diabetes and, depending on the dose and indication, for weight management, and are often launched as branded therapies after patent expiry in India.

SUNDAE is a brand of Semaglutide injection Introduced for the management of Type 2 diabetes and metabolic disorders. It is a GLP-1 receptor agonist designed to be taken as a weekly subcutaneous injection.